• Mashup Score: 21
    Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach - 8 month(s) ago

    Background: The treatment of follicular lymphoma (FL) has previously centered on chemoimmunotherapy, which can be disadvantageous due to patient intolerance, cumulative toxicities, and disease refractoriness. Targeted therapies can produce deep responses and improve progression-free and overall survival with more tolerable adverse event profiles. Methods: We summarize the current literature and key clinical trials regarding targeted therapies in follicular lymphoma both in the front-line and in the relapsed-refractory setting. Results: Targeted therapies studied in FL include immune modulators, anti-CD20 antibodies, Bruton’s tyrosine kinase (BTK) inhibitors, enhancers of zeste homolog 2 (EZH2) inhibitors, phosphoinositide 3-kinase (PI3K) inhibitors, and B-cell lymphoma 2 (BCL-2) inhibitors. Chimeric antigen receptor (CAR-T) therapy and bispecific T-cell engager (BiTE) therapies also show promise in monotherapy and in combination with targeted therapies. These therapies exhibit high ove

    Source: www.mdpi.com
    Categories: Expert Picks, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of dawood_findakly
      dawood_findakly

      RT @smbenlazar: Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach https://t.co/cbzm2d9YoO #mdpicancers via @Can…

  • Mashup Score: 24
    Maintenance therapy in acute myeloid leukemia: advances and controversies - 8 month(s) ago

    The last decade has seen steadfast progress in drug development in acute myeloid leukemia (AML) which has moved progressively towards genomic-based therapy. With these advances, outcomes in AML have improved but remains far from satisfactory. One approach towards preventing relapse in AML is to use maintenance therapy in patients, after attaining remission. Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective post-remission therapy that has been proven to reduce the risk of relapse. However, in patients who are ineligible for HSCT or have a high risk of relapse, other effective measures to prevent relapse are needed. There is also a need for post-HSCT maintenance to reduce relapse in high-risk subsets. Over the last 3 decades maintenance therapy in AML has evolved from the use of chemotherapeutic agents to more targeted therapies and better modulation of the immune system. Unfortunately, improvements in survival outcomes as a result of using these agents have not b

    Source: haematologica.org
    Categories: Expert Picks, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of dawood_findakly
      dawood_findakly

      RT @smbenlazar: Maintenance therapy in acute myeloid leukemia: advances and controversies https://t.co/7uLHICaVrB #AML #leusm https://t.co/…

  • Mashup Score: 17
    The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions - 9 month(s) ago

    The transformation of acute promyelocytic leukemia (APL) from an often fatal to highly curable cancer with long-term survival exceeding 90% is one of the greatest and most inspiring successes in oncology. A deeper understanding of the pathogenesis of APL heralded the introduction of highly effective therapies targeting the mutant protein that drives the disease, leading to the chemotherapy-free approach to cure almost all patients. In this review, we discuss the paradigm of treatment of APL in 2023, reinforce the high risk of early death without prompt initiation of treatment at first clinical suspicion, and dedicate a special focus to novel agents and future directions to improve cure rates and quality of life in patients affected by APL.

    Source: www.frontiersin.org
    Categories: Expert Picks, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of dawood_findakly
      dawood_findakly

      RT @smbenlazar: The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions https://t.co/H9JzMM7nve #l…

Load More